Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer

doi:10.1016/0140-6736(92)93150-L

The Lancet

Volume 340, Issue 8828, 7 November 1992, Pages 1120-1124

https://doi.org/10.1016/0140-6736(92)93150-L Get rights and content

Abstract

Animal models suggest a role for new vessel formation (angiogenesis) in tumours with metastatic potential, and there is some evidence that this is true for human tumours. What is needed is a sensitive and specific label for endothelial cells, and one candidate would be a monoclonal antibody to platelet/endothelial cell adhesion molecule (PECAM). We have counted microvessels in 103 primary breast cancers using the JC70 antibody to PECAM (or CD31). We compared our findings with various pathological indicators (lymph node status and tumour grade, size, and type and markers (oestrogen receptor, and c-erbB-2 expression and detection of mutant p53). Tumours showed significantly higher vascularisation than normal breast tissue and the number of blood vessels/mm² was significantly associated with node metastasis. Only 2 out of 50 tumours with 99 vessel/mm² or less were node positive whereas 31 out of 39 tumours with counts above 140/mm² were positive (p<0·0001). Tumour size and grade also correlated with node metastasis and vascularisation also increased with the size of the primary and with poor differentiation. However, within each subgroup of size or differentiation tumours without node involvement had much lower vascular counts, and multivariate analysis showed that vascular count alone explains the association of size and grade with node metastasis. Other markers, conventional or novel, did not correlate with vascularisation. Even with the short follow-up in this series, vascular counts correlated with early death. These results suggest that angiogenesis is closely linked to metastasis, that it is acquired at a critical density of vessels, and that this process occurs as tumours enlarge or become more poorly differentiated. Counting of newly formed microvessels stained with endothelium-specific antibodies may prove to be a useful tool in the early detection of metastatic potential and in the selection of patients for whom anti-angiogenesis drugs might be beneficial.

References (22)

S. Nicholson et al.
Epidermal growth factor receptor expression is associated with lack of response to endocrine therapy in patients with recurrent breast cancer
Lancet
(1989)
Ir Hart et al.
Biology of tumour metastasis
Lancet
(1992)
L. Tabar et al.
Breast cancer treatment and natural history: new insights from results of screening
Lancet
(1992)
Jg Schmidt
Natural history of breast cancer
Lancet
(1992)
J. Folkman
What is the evidence that tumours are angiogenesis dependent?
J Natl Cancer Inst
(1990)
V. Mahadevan et al.
Metastasis and angiogenesis
Acta Oncol
(1990)
E. Goldman
The growth of malignant disease in man and the lower animals with special reference to the vascular system
Lancet
(1907)
L. Liotta et al.
Quantitative relationships of intravascular tumour cells, tumour vessels, and pulmonary metastases following tumour implantation
Cancer Res
(1974)
J.R. Starkey et al.
Mast-cell-deficient W/W mice exhibit a decreased rate of tumour angiogenesis.
Int J Cancer
(1988)
A. Srivastava et al.
The prognostic significance of tumour vascularity in intermediate-thickness (076-4 mm thick) skin melanoma
Am J Pathol
(1988)

There are more references available in the full text version of this article.

Cited by (836)

Modified Bu-Fei decoction inhibits lung metastasis via suppressing angiopoietin-like 4
2022, Phytomedicine
Modified Bu-Fei decoction (MBFD), a formula of traditional Chinese medicine, is used for treating lung cancer in clinic. The actions and mechanisms of MBFD on modulating lung microenvironment is not clear.
Lung microenvironment is rich in vascular endothelial cells (ECs). This study is aimed to examine the actions of MBFD on tumor biology, and to uncover the underlying mechanisms by focusing on pulmonary ECs.
The Lewis lung carcinoma (LLC) xenograft model and the metastatic cancer model were used to determine the efficacy of MBFD on inhibiting tumor growth and metastasis. Flow cytometry and trans-well analysis were used to determine the role of ECs in anti-metastatic actions of MBFD. The in silico analysis and function assays were used to identify the mechanisms of MBFD in retarding lung metastasis. Plasma from lung cancer patients were used to verify the effects of MBFD on angiogenin-like protein 4 (ANGPTL4) in clinical conditions.
MBFD significantly suppressed spontaneous lung metastasis of LLC tumors, but not tumor growth, at clinically relevant concentrations. The anti-metastatic effects of MBFD were verified in metastatic cancer models created by intravenous injection of LLC or 4T1 cells. MBFD inhibited lung infiltration of circulating tumor cells, without reducing tumor cell proliferations in lung. In vitro, MBFD dose-dependently inhibited trans-endothelial migrations of tumor cells. RNA-seq assay and verification experiments confirmed that MBFD potently depressed endothelial ANGPTL4 which is able to broke endothelial barrier and protect tumor cells from anoikis. Database analysis revealed that high ANGPTL4 levels is negatively correlated with overall survival of cancer patients. Importantly, MBFD therapy reduced plasma levels of ANGPTL4 in lung cancer patients. Finally, MBFD was revealed to inhibit ANGPTL4 expressions in a hypoxia inducible factor-1α (HIF-1α)-dependent manner, based on results from specific signaling inhibitors and network pharmacology analysis.
MBFD, at clinically relevant concentrations, inhibits cancer lung metastasis via suppressing endothelial ANGPTL4. These results revealed novel effects and mechanisms of MBFD in treating cancer, and have a significant clinical implication of MBFD therapy in combating metastasis.
Study of angiogenesis in invasive breast carcinoma by morphometry and immunohistochemistry
2022, Medical Journal Armed Forces India
Breast cancer is the leading cause of cancer-related deaths in Asia and is emerging as the commonest female malignancy. Angiogenesis or neovascularization is important for the growth and spread of malignant tumors, and quantitative assessment of angiogenesis may prove valuable in prognostication. This study was undertaken to quantify and explore angiogenesis with immunohistochemistry with CD 34, CD 105, and vascular endothelial growth factor (VEGF), as well as morphometric analysis and correlate with the grades of the invasive breast carcinoma.
Angiogenesis was assessed by morphometry and immunohistochemistry. Seventy cases of invasive ductal carcinoma (IDC) and twenty-five benign cases as controls were included in the study. Morphometry was performed on the CD34 and CD105 (Endoglin) stained representative histologic sections with the use of a computerized digital photomicrograph system using image analyzing software. Morphometric analysis and evaluation of vascular parameters, i.e. microvessel density (MVD), microvessel caliber (VC), and total microvessel boundary density (TVBD), were calculated. Semiquantitative assessment of angiogenesis of VEGF-stained sections was done by scoring. Immunohistochemical staining was correlated with the histological grade of the tumors. MVD, mean VC, TVBD with their mean values, SD, and range were calculated using Statistical Package for The Social Sciences (Version 20). One-way analysis of variance (ANOVA) with Tukey HSD was performed to assess the difference of the parameters for the groups. Spearman rank correlation coefficients ρ were calculated.
The vascular parameters were significantly more in malignant lesions as compared to benign lesions and showed differences with increasing grade. Grades of breast carcinoma showed a mild positive correlation with VEGF (ρ = 0.467), MVD-CD34 (ρ = 0.422) and VC-CD34 (ρ = 0.482); and moderate positive correlation with TVBD-CD34 (ρ = 0.615), VC-CD105 (ρ = 0.527), and TVBD-CD105 (ρ = 0.354). When these parameters were compared with each other for all four groups, VEGF showed a mild positive correlation with MVD-CD34 (ρ = 0.295), TVBD-CD34 (ρ = 0.339), and TVBD-CD105 ((ρ = 0.277). MVD-CD105 showed a mild positive correlation with MVD-CD34 TVBD-CD105 also showed a strong positive correlation with MVD-CD34. VC-CD105 showed a moderate positive correlation with VC-CD34. CD 105 stained fewer but larger caliber vessels.
In this study, vascular parameters showed significant differences in three grades of IDC with CD34. Differences were seen in vascular parameters stained with CD105 in three grades of IDC. Expression of VEGF also showed significant differences with positive correlations in the three grades of IDC. CD34 highlighted both old and newly formed microvessels. CD 105 stained fewer but larger caliber microvessels. VC-CD105 can be an extremely useful adjunct along with VEGF and CD34 to study angiogenesis of vessels in IDC.
Controversial role of mast cells in breast cancer tumor progression and angiogenesis
2021, Clinical Breast Cancer
Breast cancer is a neoplastic disease and is a cause of cancer-related mortality for women. Among cellular and molecular regulators of the microenvironment, mast cells and vascular endothelial growth factor (VEGF), are correlated with tumor progression and prognosis in breast cancer. Clinical and experimental studies on breast cancer have revealed a marked correlation between increased angiogenesis, metastasization, and poorer prognosis. After a brief introduction on angiogenesis evidence and angiogenic factors role in different breast cancer subtypes, in this article, we have discerned the relationship between mast cell infiltration, angiogenesis, and tumor progression in human breast cancer with particular reference to the dual role of mast cells, in terms of both pro- or anti-tumoral activity and poor or good biomarker.
Anticancer potential of novel α,β-unsaturated γ-lactam derivatives targeting the PI3K/AKT signaling pathway
2021, Biochemical Pharmacology
Six recently synthesized alkyl (Z)-2-(2-oxopyrrolidin-3-ylidene)acetates were evaluated for their potential as cytotoxic and anticancer agents. All compounds were tested in the ERα positive MCF-7, triple negative MDA-MB-231, and Her2⁺ SKBR-3 breast cancer cell lines. The most lipophilic derivatives, bearing the 4-isopropylphenyl (2) or 4-tert-butylphenyl (3) group at the γ-lactam nitrogen, proved to be cytotoxic against all the cancer cell lines tested (IC₅₀ values ranging from 18 to 63 μM), exerting their greatest activity in SKBR-3 cells, with IC₅₀ values of 33 and 18 μM, respectively. Biological studies showed that the cytotoxic effects of 2 and 3 are accompanied by apoptotic death in breast cancer cells, and both compounds showed no significant toxicity on healthy cells (e.g., MCF-10A) and red blood cells. An in-depth mechanistic study based on molecular biology, immunoblotting analysis and in silico docking calculations suggested that α,β-unsaturated γ-lactam derivatives could interfere with the functioning of PI3K and PDK-1, two key enzymes in the PI3K/AKT signaling pathway, whose overactivation is related to the regulation of cell growth and survival in several malignancies.
Natural remedies and functional foods as angiogenesis modulators
2020, Functional Foods in Cancer Prevention and Therapy
The development of effective drugs and treatment strategies has great importance in keeping the human body healthy due to the existence of many diseases that do not have appropriate medical treatments available. Great scientific endeavors and government financial support, therefore, have been used to discover and design novel functional molecules and treatment modalities. Also, it is widely conceded that natural remedies and functional foods are the lead and key sources for patient welfare due to the heavy side effects of conventional treatment strategies and synthetic chemotherapeutics. Furthermore, angiogenesis is considered a key and common target for many diseases that need new capillaries or have capillary defects. We therefore would like to draw the attention of scientists more to natural remedies and functional foods that serve as angiogenesis modulators.
Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights
2024, Phytotherapy Research

View all citing articles on Scopus

View full text

ORIGINAL ARTICLESAngiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer

Abstract

Lancet

Lancet

Lancet

Lancet

What is the evidence that tumours are angiogenesis dependent?

J Natl Cancer Inst

Metastasis and angiogenesis

Acta Oncol

The growth of malignant disease in man and the lower animals with special reference to the vascular system

Lancet

Quantitative relationships of intravascular tumour cells, tumour vessels, and pulmonary metastases following tumour implantation

Cancer Res

Mast-cell-deficient W/W mice exhibit a decreased rate of tumour angiogenesis.

Int J Cancer

The prognostic significance of tumour vascularity in intermediate-thickness (076-4 mm thick) skin melanoma

Am J Pathol

ORIGINAL ARTICLES
Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer